139 related articles for article (PubMed ID: 11457665)
1. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer.
Taras TL; Wurz GT; DeGregorio MW
J Steroid Biochem Mol Biol; 2001 Jun; 77(4-5):271-9. PubMed ID: 11457665
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
Robinson SP; Jordan VC
Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
[TBL] [Abstract][Full Text] [Related]
3. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
5. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
Jordan VC; Gottardis MM; Robinson SP; Friedl A
J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.
Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC
Breast Cancer Res Treat; 1990 Feb; 15(2):95-101. PubMed ID: 2138919
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
8. Ospemifene for the treatment of dyspareunia in postmenopausal women.
Paton DM
Drugs Today (Barc); 2014 May; 50(5):357-64. PubMed ID: 24918836
[TBL] [Abstract][Full Text] [Related]
9. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
10. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Detre S; Riddler S; Salter J; A'Hern R; Dowsett M; Johnston SR
Cancer Res; 2003 Oct; 63(19):6516-22. PubMed ID: 14559845
[TBL] [Abstract][Full Text] [Related]
12. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne CK; Hobbs K; Clark GM
Cancer Res; 1985 Feb; 45(2):584-90. PubMed ID: 3967234
[TBL] [Abstract][Full Text] [Related]
13. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice.
Wärri AM; Laine AM; Majasuo KE; Alitalo KK; Härkönen PL
Int J Cancer; 1991 Oct; 49(4):616-23. PubMed ID: 1680817
[TBL] [Abstract][Full Text] [Related]
14. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).
Shibata J; Toko T; Saito H; Lykkesfeldt AE; Fujioka A; Sato K; Hashimoto A; Wierzba K; Yamada Y
Cancer Chemother Pharmacol; 2000; 45(2):133-41. PubMed ID: 10663628
[TBL] [Abstract][Full Text] [Related]
15. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice.
Ju YH; Fultz J; Allred KF; Doerge DR; Helferich WG
Carcinogenesis; 2006 Apr; 27(4):856-63. PubMed ID: 16399773
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
17. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
18. Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo.
Sipila PE; Wiebe VJ; Hubbard GB; Koester SK; Emshoff VD; Maenpaa JU; Wurz GT; Seymour RC; DeGregorio MW
Eur J Cancer; 1993; 29A(15):2138-44. PubMed ID: 8297653
[TBL] [Abstract][Full Text] [Related]
19. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
Zhang L; Kharbanda S; Hanfelt J; Kern FG
Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
[TBL] [Abstract][Full Text] [Related]
20. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]